Abstract
Imiquimod, the lead compound of the imidazoquinoline family of nucleoside analogues, has shown good efficacy against a variety of tumors of different origin. The mode of action of imiquimod and related compounds, which we have begun to understand in some detail in recent years, is complex and interesting inasmuch as it appears to comprise several presumably mutually enhancing components. Predominant amongst its actions is the induction of pro-inflammatory cytokines through agonistic activity towards Tolllike receptor (TLR)-7 and TLR-8, and consecutively, activation of the central transcription factor NF- κB. This activity stimulates the production of pro-inflammatory cytokines, chemokines and other mediators resulting in activation of antigen- presenting cells and the mounting of a profound Th1-weighted antitumoral cellular immune response. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of NF-κB. The pro-inflammatory activity of imiquimod appears to be augmented by suppression of a negative regulatory feedback mechanism which normally limits inflammatory responses. This is achieved independent of TLR-7 and TLR-8 through interference with adenosine receptor signaling pathways, particularly the A2A subtype, and receptor-independent reduction of adenylyl cyclase activity. Finally, at higher, albeit therapeutically relevant concentrations, imiquimod exerts a pro-apoptotic activitiy against tumor cells. Induction of apoptosis by imiquimod appears to be dependent on Bcl-2 proteins and involves caspase activation. The combination of multiple, presumably synergistic anti-tumoral functions by a single compound represents an interesting principle of pathogenesis-oriented, anti-neoplastic therapy.
Keywords: inflammatory cytokines, transcription, Toll like receptors, immune response, Pro-Apoptotic
Current Medicinal Chemistry
Title: The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Volume: 14 Issue: 6
Author(s): Margarete Schon and Michael P. Schon
Affiliation:
Keywords: inflammatory cytokines, transcription, Toll like receptors, immune response, Pro-Apoptotic
Abstract: Imiquimod, the lead compound of the imidazoquinoline family of nucleoside analogues, has shown good efficacy against a variety of tumors of different origin. The mode of action of imiquimod and related compounds, which we have begun to understand in some detail in recent years, is complex and interesting inasmuch as it appears to comprise several presumably mutually enhancing components. Predominant amongst its actions is the induction of pro-inflammatory cytokines through agonistic activity towards Tolllike receptor (TLR)-7 and TLR-8, and consecutively, activation of the central transcription factor NF- κB. This activity stimulates the production of pro-inflammatory cytokines, chemokines and other mediators resulting in activation of antigen- presenting cells and the mounting of a profound Th1-weighted antitumoral cellular immune response. In addition, there are a number of secondary effects on the molecular and cellular level that can be explained through the activation of NF-κB. The pro-inflammatory activity of imiquimod appears to be augmented by suppression of a negative regulatory feedback mechanism which normally limits inflammatory responses. This is achieved independent of TLR-7 and TLR-8 through interference with adenosine receptor signaling pathways, particularly the A2A subtype, and receptor-independent reduction of adenylyl cyclase activity. Finally, at higher, albeit therapeutically relevant concentrations, imiquimod exerts a pro-apoptotic activitiy against tumor cells. Induction of apoptosis by imiquimod appears to be dependent on Bcl-2 proteins and involves caspase activation. The combination of multiple, presumably synergistic anti-tumoral functions by a single compound represents an interesting principle of pathogenesis-oriented, anti-neoplastic therapy.
Export Options
About this article
Cite this article as:
Schon Margarete and Schon P. Michael, The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines, Current Medicinal Chemistry 2007; 14 (6) . https://dx.doi.org/10.2174/092986707780059625
DOI https://dx.doi.org/10.2174/092986707780059625 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry DNA Repair Proteins as Molecular Therapeutics for Oxidative and Alkylating Lung Injury
Current Gene Therapy Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets BRCA1 as Target for Breast Cancer Prevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Vascular Adenosine Receptors; Potential Clinical Applications
Current Vascular Pharmacology